Vyne Therapeutics Inc Stock Price, News & Analysis

VYNE Therapeutics Inc. (Nasdaq: VYNE) will report its financial results for Q2 2021 on August 12, 2021, before the market opens. A conference call is scheduled for 8:30 a.m. ET to discuss these results and provide a corporate update. VYNE focuses on developing innovative therapies, including FDA-approved products AMZEEQ® and ZILXI®, utilizing its proprietary Molecule Stabilizing Technology (MST™). For further details, visit their website or follow their upcoming call.

VYNE Therapeutics Inc. has initiated a clinical trial for AMZEEQ (minocycline) topical foam, 4%, as a companion treatment with oral isotretinoin in patients with moderate to severe acne. Conducted at the Austin Institute for Clinical Research, the trial aims to assess safety, efficacy, and tolerability over a 20-week treatment period. The study will also evaluate AMZEEQ's impact on common adverse reactions of isotretinoin. Approximately 30 patients will be enrolled. AMZEEQ already has FDA approval for treating inflammatory lesions of acne vulgaris.

VYNE Therapeutics announced that Dr. Iain Stuart will moderate a scientific panel discussion at the 2nd Annual JAK Inhibitors Drug Development Digital Event, occurring from June 29 to July 1, 2021. The discussion, set for June 30 at 2:40 PM Eastern Time, will focus on combinational opportunities with JAK inhibitors and ongoing research trends in immunology. The event aims to address the lack of JAK inhibitors in specific disease profiles and explore the potential benefits of combination therapeutic approaches.

VYNE Therapeutics announced its Q1 2021 financial results, reporting revenues of $4.1 million, a significant increase from $1.8 million in Q1 2020, primarily driven by the launches of AMZEEQ and ZILXI. The net loss narrowed to $20.6 million compared to $40.2 million in the prior year. VYNE plans to initiate a Phase 2a study for FMX114, a new treatment for atopic dermatitis, in Q3 2021. The company also raised $73.1 million through a stock offering and executed a 1-for-4 reverse stock split, strengthening its cash position to $120.4 million.

VYNE Therapeutics Inc. (Nasdaq: VYNE) announced it will report its financial results for Q1 2021 on May 6, 2021, before market opens. A conference call will follow at 8:30 a.m. ET to discuss these results and provide a corporate update. VYNE focuses on developing innovative dermatological therapies, having received FDA approvals for AMZEEQ® and ZILXI®. Investors can access a replay of the call on VYNE's website post-event.

VYNE Therapeutics announced that CEO David Domzalski will present at the Barclays Global Healthcare Conference and H.C. Wainwright Global Life Sciences Conference on March 9, 2021. The Barclays conference will include a fireside chat at 8:00 AM Eastern Time, with a webcast available at this link. The H.C. Wainwright conference will be available on demand starting at 7:00 AM Eastern Time on the same day, with a webcast link at this link.

VYNE Therapeutics reported financial results for Q4 and the full year of 2020, showing revenues of $21 million, up from $0.4 million in 2019. The company's net loss was $255.6 million, driven by significant expenses from R&D and impairments. VYNE launched its topical products ZILXI and AMZEEQ, gaining market traction in acne and rosacea. Key developments include plans for a Phase 3 trial for FCD105 and a Phase 2a study for FMX114 targeting atopic dermatitis, expected to yield results by year-end. The company has sufficient cash to fund operations through 2022.

VYNE Therapeutics Inc. announced that CEO David Domzalski will present at the Cowen 41st Annual Health Care Conference on March 2, 2021, at 2:10 PM ET. The presentation will be in a fireside chat format, providing insights into the company's innovative therapies in dermatology, including AMZEEQ® and ZILXI®, both FDA-approved minocycline products. For those interested, the webcast link is here. VYNE aims to enhance the lives of patients through proprietary therapies.

VYNE Therapeutics announced promising preclinical data for FMX114, a topical gel designed to treat mild-to-moderate atopic dermatitis (AD). The Phase 2a clinical study is set to begin in the third quarter of 2021, with top-line results expected by year-end. In animal studies, FMX114 demonstrated an 89% reduction in the modified atopic dermatitis index score compared to control. VYNE plans to discuss further details during the year-end earnings call on March 4, 2021.